US20080160169A1 - Coating device and method for coating medical device with bioactive peptide - Google Patents
Coating device and method for coating medical device with bioactive peptide Download PDFInfo
- Publication number
- US20080160169A1 US20080160169A1 US11/963,677 US96367707A US2008160169A1 US 20080160169 A1 US20080160169 A1 US 20080160169A1 US 96367707 A US96367707 A US 96367707A US 2008160169 A1 US2008160169 A1 US 2008160169A1
- Authority
- US
- United States
- Prior art keywords
- cylinder
- syringe
- bioactive peptide
- valve
- connector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]C[3*][2*]([1*])[2*]([3*]C[1*])[Y]C[4*] Chemical compound [1*]C[3*][2*]([1*])[2*]([3*]C[1*])[Y]C[4*] 0.000 description 2
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/02—Inorganic materials
- A61L27/12—Phosphorus-containing materials, e.g. apatite
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/227—Other specific proteins or polypeptides not covered by A61L27/222, A61L27/225 or A61L27/24
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
- A61L27/34—Macromolecular materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/507—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials for artificial blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2430/00—Materials or treatment for tissue regeneration
- A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants
Definitions
- the present invention relates generally to the field of a system and method for coating medical devices with coating materials.
- Implantable medical devices are frequently used in a variety of reparative and regenerative medical procedures. Use of bioactive peptides in concert with these devices is one way to improve the performance of the device.
- sample preparation methods especially with regard to the application of the peptide coating, are difficult to control but require accuracy and precision.
- a coating device to apply a fine, uniform coating of onto the implantable in order to simplify the sample preparation process.
- a method for coating a medical device with a bioactive peptide comprising providing a medical device to be coated with a bioactive peptide to a cylinder having a plunger that inserts into a first end of the cylinder and fits snuggly against the sides of the cylinder and at the other end of the cylinder is located a connector having a first valve that is attached to the second end of the cylinder for creating a closed cylinder when the first valve is closed; attaching a syringe containing a bioactive peptide coating solution to a second valve of the connector; introducing into the cylinder the bioactive peptide coating solution when the first valve of the connector and the second valve of the connector are open; incubating the medical device within the cylinder with the bioactive peptide coating solution; removing the bioactive peptide coating solution from the cylinder after the medical device is coated with the bioactive peptide.
- the step of incubating further comprises placing the cylinder in a substantially horizontal position to increase the solution to granule contact.
- the cylinder is a first syringe.
- the medical device is osteoconductive material.
- the cylinder is in a substantially vertical position during the introducing step.
- the plunger of the cylinder is pushed to discharge the bioactive peptide coating solution from the cylinder.
- the bioactive peptide coating solution comprises a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor.
- Another embodiment of the present invention is a system for coating a medical device with a bioactive peptide
- a cylinder for housing a medical device to be coated with a bioactive peptide coating solution
- the cylinder comprises a plunger that inserts into a first end of the cylinder and fits snuggly against the sides of the cylinder and at the other end of the cylinder is located a connector having a first valve that is attached to the second end of the cylinder for creating a closed cylinder when the first valve is closed; a syringe that is attached to a second valve of the connector wherein the syringe contains a bioactive peptide coating solution that is introduced into the cylinder via the connector; and a connector having a first valve attached to the cylinder and a second valve attached to the syringe.
- kits for use in coating a medical device with a bioactive peptide comprises a bioactive peptide; a first syringe; a second syringe and a connector having a first valve and a second valve.
- the bioactive peptide comprises a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor.
- One aspect of the present invention provides an improved bioactive peptide coating method for medical devices.
- Another aspect of the present invention provides for use of bioactive peptides in concert with implantable medical devices to improve the performance of the medical device.
- Another aspect of the present invention provides improved methods for application of the peptide coating to medical devices.
- Another aspect of the present invention provides for a method of accurately applying a bioactive peptide coating device to an implantable medical device.
- FIG. 1 illustrates a coating device according to one embodiment of the present invention.
- the present invention is a coating device system.
- the system comprises a container, typically a cylinder, for example a syringe.
- the syringe is attached to a connector at one end.
- the connector may be a valve used to turn on, turn off, or regulate the flow of a fluid in a cylinder.
- the valve may be a stop cock for example a multi-way stop cock.
- the multi-way stop cock is a three way stop cock valve.
- the cylinder may be a syringe capable of receiving a plunger with a head that is sized to fit snugly against the sides of the syringe barrel to push liquid and particles through the syringe barrel toward the tip.
- the container is capable of housing a medical device referred to herein as materials to be treated.
- the container may be vented at one end.
- the container may also be a syringe barrel with an enclosed medical device which is closured with a second syringe barrel.
- the container in all cases houses the medical device.
- the container is a syringe that is identical in shape and volume capacity to the second syringe but is not limited thereto as other volume capacities and shapes will function equivalently.
- the container with the materials to be coated therein is placed in a substantially vertical position and is attached at one end to one of the valves of the connector.
- a syringe containing an appropriate coating solution is attached to a second of the valves of the connector.
- the solution is introduced into the container housing the materials to be coated.
- the solution fills the container from the bottom up.
- the coating is allowed to incubate with the material to be coated for an appropriate length of time.
- the coating solution is then removed by withdrawing the solution back into the syringe or by pushing the solution out of the container with the container plunger.
- the coated material is then removed from the container and is ready for use.
- the container is a syringe with graduated markings allowing additional materials, such as bone chips, to be added and measured.
- the container may house a material which requires pre-wetting.
- a wetting syringe may be used, in that case, to introduce a wetting solution prior to the coating process.
- a rinsing syringe may be used to introduce into the container a separate rinse for the coated device to remove residual unbound materials.
- a container 5 contains a medical device (not shown) that is the target of a bioactive peptide coating solution.
- the container 5 has a plunger 3 inserted into a first end.
- a connector valve 7 on connector 15 At the second end of the container 5 is attached a connector valve 7 on connector 15 .
- a syringe 17 having a syringe barrel 11 and a plunger 13 contains a bioactive peptide coating solution.
- the tip of the syringe is attached to a connector valve 9 on connector 15 .
- Plunger 13 forces bioactive peptide coating solution (not shown) into the container 5 containing the medical device to be coated.
- plunger 3 is depressed to discharge the bioactive peptide solution from container 5 .
- Hydroxyapatite/tricalcium phosphate granules with nominal diameters of 1-2 mm where placed in a first 20 ml syringe barrel (referred to in example 1 as syringe A) wherein the barrel is attached to a 3-way valve connector at its tip.
- the plunger of the barrel is replaced with care not to compress the granules.
- the first 20 ml syringe barrel is placed in an upright position.
- a second 20 ml syringe (referred to in example 1 as syringe B) with an attached needle is used to draw 6 ml of the peptide coating solution from a vial.
- the needle is removed from the second syringe containing the coating solution and the second syringe is attached to a first valve of the 3-way valve connector that is already connected to syringe A thereby connecting the syringe A to syringe B via the 3-way valve connector.
- the valves connected to the syringe A and syringe B are opened and the coating solution is introduced into syringe A.
- the material housed in syringe A is mixed with solution comprising a bioactive peptide.
- Both syringes are positioned on their sides to achieve improved solution-to-granule contact during incubation.
- the material and coating solution are incubated together for the appropriate incubation time with periodic mixing, for example 15 minutes.
- the syringe A is returned to a substantially vertical position.
- the plunger of syringe A is slowly depressed so that the plunger pushes the coating solution back into syringe B. Air from within syringe A can be pushed across the granules to improve solution removal. Syringe B is then disconnected from the connector.
- the syringe plunger from syringe A can be removed and bone chips added to the desired volume (for example 5 cc). Once measured the contents of the syringe barrel can be removed into a surgical tray for final mixing and placement.
- a small-bore ePTFE vascular graft is placed in a 10 ml syringe barrel wherein the barrel had an attached 3-way valve.
- a black rubber stopper was placed in the opening of the barrel. Through the stopper a venting needle is positioned with an attached 0.22 micron filter and is referred to in example 2 as syringe A.
- Syringe A is placed in an upright position.
- a second 20 ml syringe (referred to in example 2 as syringe B) with an attached needle about 6 ml of the ePTFE wetting solution is drawn into syringe B.
- the needle is then removed from syringe B and syringe B is attached to syringe A with their female adopters in the three way stopcock.
- the valves attached to the syringes are opened and the wetting solution is introduced into syringe A.
- the wetting solution is subsequently removed from syringe A and into syringe B by pulling on the plunger of syringe B.
- Syringe B can be removed from the valve of the three way stop cock.
- syringe C Using a fresh 10 ml syringe prefilled with a peptide coating solution (referred to in example 2 as syringe C), connect syringe C to syringe A with their female adopters in the three way stopcock. Introduce the coating solution in syringe C into the bottom of syringe A. Incubate the coating solution with the ePTFE for about 15 minutes with periodic mixing. Using syringe C, remove the coating solution. Remove the black rubber stopper. The coated vascular graft can be removed into a surgical tray for subsequent placement.
- a peptide coating solution referred to in example 2 as syringe C
- ePTFE tissue patch was placed in a 20 ml syringe barrel wherein the barrel had an attached 3-way valve.
- a black rubber stopper was placed in the opening of the barrel. Through the stopper was placed a venting needle with an attached 0.22 micron filter. This device will be referred to as syringe A for Example 3.
- Syringe A in placed in a substantially upright position.
- a separate 20 ml syringe referred to as syringe B in example 3
- syringe B Using a separate 20 ml syringe (referred to as syringe B in example 3) with an attached needle 15 ml of the ePTFE wetting solution is withdraw into syringe B.
- the needle is removed and the syringe is attached to a female adopter in the three way stopcock.
- the valve is opened and the wetting solution is introduced into syringe A.
- the wetting solution is removed by pulling on the plunger of syringe B.
- Syringe B is removed from the connector.
- a fresh 20 ml syringe prefilled with a peptide coating solution (referred to as syringe C in example 3) is connected to syringe A with their female adopters in the three way stopcock.
- syringe C a peptide coating solution
- the valves of the connector When the valves of the connector are in the open position, the peptide coating solution is introduced into the barrel of syringe A.
- the solution and the contents of syringe A are incubated for 15 minutes with periodic mixing.
- the coating solution is removed. Remove the black rubber stopper.
- the coated patch can be removed into a surgical tray for subsequent placement.
- X is a peptide chain that (i) has a minimum of three amino acid residues, (ii) has a maximum of about fifty amino acid residues, and (iii) binds specifically to a specifically to a cell surface receptor;
- R 1 is independently hydrogen, such that the terminal group is NH 2 , an acyl group with a linear or branched C 1 to C 17 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH 2 , NH 3 + , or NH group or a corresponding acylated derivative, or is amino acid, a dipeptide or a tripeptide with an N-terminus NH 2 , NH 3 + , or NH group;
- R 2 is independently a trifunctional alpha amino acid residue, wherein X is covalently bonded through a side chain of R 2 ;
- R 3 is independently a linker comprising a chain from 0 to about 15 backbone atoms covalently bonded to R 2 ;
- R 4 is OH such that the terminal group is a carboxyl, NH 2 , an acyl group with a linear or branched C 1 to C 17 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH 2 , NH 3 + , or NH group or a corresponding acylated derivative, or NH—R 1 ;
- Y is a linker comprising a chain from 0 to about 50 backbone atoms covalently bonded to R 2 and Z;
- Z is a non-signaling peptide chain that includes a heparin binding domain comprising an amino acid sequence that comprises (i) a minimum of one heparin binding motif, (ii) a maximum of about ten heparin binding motifs, and (iii) a maximum of about thirty amino acids.
- X is a peptide chain that (i) has a minimum of three amino acid residues, (ii) has a maximum of about fifty amino acid residues, and (iii) binds specifically to a specifically to a cell surface receptor;
- R 1 is independently hydrogen, such that the terminal group is NH 2 , an acyl group with a linear or branched C 1 to C 17 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH 2 , NH 3 + , or NH group or a corresponding acylated derivative, or is amino acid, a dipeptide or a tripeptide with an N-terminus NH 2 , NH 3 + , or NH group;
- R 6 is independently a linker comprising a chain from 0 to about 15 backbone atoms covalently bonded to R 3 when the linker is greater than 0 atoms;
- R 5 is a trifunctional alpha amino acid residue, wherein X is covalently bonded through a side chain of R 3 ;
- R 4 is OH such that the terminal group is a carboxyl, NH 2 , an acyl group with a linear or branched C 1 to C 17 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH 2 , NH 3 + , or NH group or a corresponding acylated derivative, or NH—R 1 ;
- Y is a linker comprising a chain from 0 to about 50 backbone atoms covalently bonded to R 5 and Z;
- Z is a non-signaling peptide chain that includes a heparin binding domain comprising an amino acid sequence that comprises (i) a minimum of one heparin binding motif, (ii) a maximum of about ten heparin binding motifs, and (iii) a maximum of about thirty amino acids.
- the bioactive peptide comprises a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor.
Abstract
A method for coating a medical device with a bioactive peptide comprising: providing a medical device to be coated with a bioactive peptide to a cylinder; attaching a syringe containing a bioactive peptide coating solution; introducing into the cylinder the bioactive peptide coating solution when the first valve of the connector and the second valve of the connector are open; incubating the medical device within the cylinder with the bioactive peptide coating solution; removing the bioactive peptide coating solution from the cylinder after the medical device is coated with the bioactive peptide.
Description
- This application is a continuation-in-part application of U.S. patent application Ser. No. 11/767,391, entitled “COMPOSITION AND METHOD FOR DELIVERY OF A PARTIAL AGONIST OF BMP-2 FOR ENHANCEMENT OF OSTEOGENESIS”, filed on Jun. 22, 2007 which claims priority to and the benefit of the filing of U.S. Provisional Patent Application Ser. No. 60/805,594, entitled “COMPOSITION AND METHOD FOR DELIVERY OF A PARTIAL AGONIST OF BMP-2 FOR ENHANCEMENT OF OSTEOGENESIS”, filed on Jun. 22, 2006, and the specification and claims thereof are incorporated herein by reference.
- The present invention relates generally to the field of a system and method for coating medical devices with coating materials.
- Implantable medical devices are frequently used in a variety of reparative and regenerative medical procedures. Use of bioactive peptides in concert with these devices is one way to improve the performance of the device. However, sample preparation methods, especially with regard to the application of the peptide coating, are difficult to control but require accuracy and precision. There is a need for a coating device to apply a fine, uniform coating of onto the implantable in order to simplify the sample preparation process.
- According to one embodiment of the present invention a method for coating a medical device with a bioactive peptide comprising providing a medical device to be coated with a bioactive peptide to a cylinder having a plunger that inserts into a first end of the cylinder and fits snuggly against the sides of the cylinder and at the other end of the cylinder is located a connector having a first valve that is attached to the second end of the cylinder for creating a closed cylinder when the first valve is closed; attaching a syringe containing a bioactive peptide coating solution to a second valve of the connector; introducing into the cylinder the bioactive peptide coating solution when the first valve of the connector and the second valve of the connector are open; incubating the medical device within the cylinder with the bioactive peptide coating solution; removing the bioactive peptide coating solution from the cylinder after the medical device is coated with the bioactive peptide. In a preferred embodiment the step of incubating further comprises placing the cylinder in a substantially horizontal position to increase the solution to granule contact. In another preferred embodiment the cylinder is a first syringe. In another preferred embodiment the medical device is osteoconductive material. In yet another preferred embodiment the cylinder is in a substantially vertical position during the introducing step. In another preferred embodiment the plunger of the cylinder is pushed to discharge the bioactive peptide coating solution from the cylinder. In still another preferred embodiment the bioactive peptide coating solution comprises a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor.
- Another embodiment of the present invention is a system for coating a medical device with a bioactive peptide comprising a cylinder for housing a medical device to be coated with a bioactive peptide coating solution wherein the cylinder comprises a plunger that inserts into a first end of the cylinder and fits snuggly against the sides of the cylinder and at the other end of the cylinder is located a connector having a first valve that is attached to the second end of the cylinder for creating a closed cylinder when the first valve is closed; a syringe that is attached to a second valve of the connector wherein the syringe contains a bioactive peptide coating solution that is introduced into the cylinder via the connector; and a connector having a first valve attached to the cylinder and a second valve attached to the syringe.
- In yet another embodiment of the present invention comprises a kit for use in coating a medical device with a bioactive peptide comprises a bioactive peptide; a first syringe; a second syringe and a connector having a first valve and a second valve. In a preferred embodiment, the bioactive peptide comprises a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor.
- One aspect of the present invention provides an improved bioactive peptide coating method for medical devices.
- Another aspect of the present invention provides for use of bioactive peptides in concert with implantable medical devices to improve the performance of the medical device.
- Another aspect of the present invention provides improved methods for application of the peptide coating to medical devices.
- Another aspect of the present invention provides for a method of accurately applying a bioactive peptide coating device to an implantable medical device.
- Additional objects and advantages of the present invention will be apparent in the following detailed description read in conjunction with the accompanying drawing figures.
- The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.
-
FIG. 1 illustrates a coating device according to one embodiment of the present invention. - One embodiment of the present invention is a coating device system. The system comprises a container, typically a cylinder, for example a syringe. The syringe is attached to a connector at one end. The connector may be a valve used to turn on, turn off, or regulate the flow of a fluid in a cylinder. The valve may be a stop cock for example a multi-way stop cock. In a preferred embodiment the multi-way stop cock is a three way stop cock valve. The cylinder may be a syringe capable of receiving a plunger with a head that is sized to fit snugly against the sides of the syringe barrel to push liquid and particles through the syringe barrel toward the tip.
- The container is capable of housing a medical device referred to herein as materials to be treated. The container may be vented at one end. The container may also be a syringe barrel with an enclosed medical device which is closured with a second syringe barrel. The container in all cases houses the medical device. In a preferred embodiment the container is a syringe that is identical in shape and volume capacity to the second syringe but is not limited thereto as other volume capacities and shapes will function equivalently.
- According to another embodiment, the container with the materials to be coated therein is placed in a substantially vertical position and is attached at one end to one of the valves of the connector. A syringe containing an appropriate coating solution is attached to a second of the valves of the connector. The solution is introduced into the container housing the materials to be coated. The solution fills the container from the bottom up. The coating is allowed to incubate with the material to be coated for an appropriate length of time. The coating solution is then removed by withdrawing the solution back into the syringe or by pushing the solution out of the container with the container plunger. The coated material is then removed from the container and is ready for use.
- In a preferred embodiment the container is a syringe with graduated markings allowing additional materials, such as bone chips, to be added and measured.
- In some cases the container may house a material which requires pre-wetting. A wetting syringe may be used, in that case, to introduce a wetting solution prior to the coating process. Similarly, a rinsing syringe may be used to introduce into the container a separate rinse for the coated device to remove residual unbound materials.
- Referring now to
FIG. 1 , acontainer 5 contains a medical device (not shown) that is the target of a bioactive peptide coating solution. Thecontainer 5 has aplunger 3 inserted into a first end. At the second end of thecontainer 5 is attached aconnector valve 7 onconnector 15. Asyringe 17 having asyringe barrel 11 and aplunger 13 contains a bioactive peptide coating solution. The tip of the syringe is attached to aconnector valve 9 onconnector 15. Plunger 13 forces bioactive peptide coating solution (not shown) into thecontainer 5 containing the medical device to be coated. After incubation of the bioactive peptide solution with the medical device incontainer 5,plunger 3 is depressed to discharge the bioactive peptide solution fromcontainer 5. - Hydroxyapatite/tricalcium phosphate granules with nominal diameters of 1-2 mm where placed in a first 20 ml syringe barrel (referred to in example 1 as syringe A) wherein the barrel is attached to a 3-way valve connector at its tip. The plunger of the barrel is replaced with care not to compress the granules. The first 20 ml syringe barrel is placed in an upright position.
- A second 20 ml syringe (referred to in example 1 as syringe B) with an attached needle is used to draw 6 ml of the peptide coating solution from a vial. The needle is removed from the second syringe containing the coating solution and the second syringe is attached to a first valve of the 3-way valve connector that is already connected to syringe A thereby connecting the syringe A to syringe B via the 3-way valve connector. The valves connected to the syringe A and syringe B are opened and the coating solution is introduced into syringe A. The material housed in syringe A is mixed with solution comprising a bioactive peptide. Both syringes are positioned on their sides to achieve improved solution-to-granule contact during incubation. The material and coating solution are incubated together for the appropriate incubation time with periodic mixing, for example 15 minutes. The syringe A is returned to a substantially vertical position. The plunger of syringe A is slowly depressed so that the plunger pushes the coating solution back into syringe B. Air from within syringe A can be pushed across the granules to improve solution removal. Syringe B is then disconnected from the connector.
- The syringe plunger from syringe A can be removed and bone chips added to the desired volume (for example 5 cc). Once measured the contents of the syringe barrel can be removed into a surgical tray for final mixing and placement.
- A small-bore ePTFE vascular graft is placed in a 10 ml syringe barrel wherein the barrel had an attached 3-way valve. A black rubber stopper was placed in the opening of the barrel. Through the stopper a venting needle is positioned with an attached 0.22 micron filter and is referred to in example 2 as syringe A.
- Syringe A is placed in an upright position. Using a second 20 ml syringe (referred to in example 2 as syringe B) with an attached needle about 6 ml of the ePTFE wetting solution is drawn into syringe B. The needle is then removed from syringe B and syringe B is attached to syringe A with their female adopters in the three way stopcock. The valves attached to the syringes are opened and the wetting solution is introduced into syringe A. The wetting solution is subsequently removed from syringe A and into syringe B by pulling on the plunger of syringe B. Syringe B can be removed from the valve of the three way stop cock.
- Using a fresh 10 ml syringe prefilled with a peptide coating solution (referred to in example 2 as syringe C), connect syringe C to syringe A with their female adopters in the three way stopcock. Introduce the coating solution in syringe C into the bottom of syringe A. Incubate the coating solution with the ePTFE for about 15 minutes with periodic mixing. Using syringe C, remove the coating solution. Remove the black rubber stopper. The coated vascular graft can be removed into a surgical tray for subsequent placement.
- An ePTFE tissue patch was placed in a 20 ml syringe barrel wherein the barrel had an attached 3-way valve. A black rubber stopper was placed in the opening of the barrel. Through the stopper was placed a venting needle with an attached 0.22 micron filter. This device will be referred to as syringe A for Example 3.
- Syringe A in placed in a substantially upright position. Using a separate 20 ml syringe (referred to as syringe B in example 3) with an attached
needle 15 ml of the ePTFE wetting solution is withdraw into syringe B. The needle is removed and the syringe is attached to a female adopter in the three way stopcock. The valve is opened and the wetting solution is introduced into syringe A. After sufficient time to allow wetting of the material to be coated with the bioactive peptide coating solution, the wetting solution is removed by pulling on the plunger of syringe B. Syringe B is removed from the connector. - A fresh 20 ml syringe prefilled with a peptide coating solution (referred to as syringe C in example 3) is connected to syringe A with their female adopters in the three way stopcock. When the valves of the connector are in the open position, the peptide coating solution is introduced into the barrel of syringe A. The solution and the contents of syringe A are incubated for 15 minutes with periodic mixing. Using syringe C the coating solution is removed. Remove the black rubber stopper. The coated patch can be removed into a surgical tray for subsequent placement.
- In one embodiment of the present invention the bioactive peptide comprises a compound of formula I
- wherein:
- X is a peptide chain that (i) has a minimum of three amino acid residues, (ii) has a maximum of about fifty amino acid residues, and (iii) binds specifically to a specifically to a cell surface receptor;
- R1 is independently hydrogen, such that the terminal group is NH2, an acyl group with a linear or branched C1 to C17 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH2, NH3 +, or NH group or a corresponding acylated derivative, or is amino acid, a dipeptide or a tripeptide with an N-terminus NH2, NH3 +, or NH group;
- R2 is independently a trifunctional alpha amino acid residue, wherein X is covalently bonded through a side chain of R2;
- R3 is independently a linker comprising a chain from 0 to about 15 backbone atoms covalently bonded to R2;
- R4 is OH such that the terminal group is a carboxyl, NH2, an acyl group with a linear or branched C1 to C17 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH2, NH3 +, or NH group or a corresponding acylated derivative, or NH—R1;
- Y is a linker comprising a chain from 0 to about 50 backbone atoms covalently bonded to R2 and Z; and
- Z is a non-signaling peptide chain that includes a heparin binding domain comprising an amino acid sequence that comprises (i) a minimum of one heparin binding motif, (ii) a maximum of about ten heparin binding motifs, and (iii) a maximum of about thirty amino acids.
- In another embodiment the bioactive peptide comprises a compound of formula II comprising:
- wherein:
- X is a peptide chain that (i) has a minimum of three amino acid residues, (ii) has a maximum of about fifty amino acid residues, and (iii) binds specifically to a specifically to a cell surface receptor;
- R1 is independently hydrogen, such that the terminal group is NH2, an acyl group with a linear or branched C1 to C17 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH2, NH3 +, or NH group or a corresponding acylated derivative, or is amino acid, a dipeptide or a tripeptide with an N-terminus NH2, NH3 +, or NH group;
- R6 is independently a linker comprising a chain from 0 to about 15 backbone atoms covalently bonded to R3 when the linker is greater than 0 atoms;
- R5 is a trifunctional alpha amino acid residue, wherein X is covalently bonded through a side chain of R3;
- R4 is OH such that the terminal group is a carboxyl, NH2, an acyl group with a linear or branched C1 to C17 alkyl, aryl, heteroaryl, alkene, alkenyl or aralkyl chain including an N-terminus NH2, NH3 +, or NH group or a corresponding acylated derivative, or NH—R1;
- Y is a linker comprising a chain from 0 to about 50 backbone atoms covalently bonded to R5 and Z; and
- Z is a non-signaling peptide chain that includes a heparin binding domain comprising an amino acid sequence that comprises (i) a minimum of one heparin binding motif, (ii) a maximum of about ten heparin binding motifs, and (iii) a maximum of about thirty amino acids.
- In another embodiment the bioactive peptide comprises a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor.
- The present invention has been described in terms of preferred embodiments, however, it will be appreciated that various modifications and improvements may be made to the described embodiments without departing from the scope of the invention. The entire disclosures of all references, applications, patents, and publications cited above and/or in the attachments, and of the corresponding application(s), are hereby incorporated by reference.
Claims (10)
1. A method for coating a medical device with a bioactive peptide comprising:
providing a medical device to be coated with a bioactive peptide to a cylinder having a plunger that inserts into a first end of the cylinder and fits snuggly against the sides of the cylinder and at the other end of the cylinder is located a connector having a first valve that is attached to the second end of the cylinder for creating a closed cylinder when the first valve is closed;
attaching a syringe containing a bioactive peptide coating solution to a second valve of the connector;
introducing into the cylinder the bioactive peptide coating solution when the first valve of the connector and the second valve of the connector are open;
incubating the medical device within the cylinder with the bioactive peptide coating solution;
removing the bioactive peptide coating solution from the cylinder after the medical device is coated with the bioactive peptide.
2. The method of claim 1 wherein the step of incubating further comprises placing the cylinder in a substantially horizontal position to increase the solution to granule contact.
3. The method of claim 1 wherein the cylinder is a first syringe.
4. The method of claim 1 wherein the medical device is osteoconductive material.
5. The method of claim 1 wherein the cylinder is in a substantially vertical position during the introducing step.
6. The method of claim 1 wherein the plunger of the cylinder is pushed to discharge the bioactive peptide coating solution from the cylinder.
7. The method of claim 1 wherein the bioactive peptide coating solution comprises a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor.
8. A system for coating a medical device with a bioactive peptide comprising:
a cylinder for housing a medical device to be coated with a bioactive peptide coating solution wherein the cylinder comprises a plunger that inserts into a first end of the cylinder and fits snuggly against the sides of the cylinder and at the other end of the cylinder is located a connector having a first valve that is attached to the second end of the cylinder for creating a closed cylinder when the first valve is closed;
a syringe that is attached to a second valve of the connector wherein the syringe contains a bioactive peptide coating solution that is introduced into the cylinder via the connector; and
a connector having a first valve attached to the cylinder and a second valve attached to the syringe.
9. A kit for use in coating a medical device with a bioactive peptide comprising:
a bioactive peptide;
a first syringe;
a second syringe and
a connector having a first valve and a second valve.
10. The kit of claim 9 wherein the bioactive peptide comprises a synthetic growth factor analogue comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/963,677 US20080160169A1 (en) | 2006-06-22 | 2007-12-21 | Coating device and method for coating medical device with bioactive peptide |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80559406P | 2006-06-22 | 2006-06-22 | |
US11/767,391 US7981862B2 (en) | 2003-08-19 | 2007-06-22 | Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US11/963,677 US20080160169A1 (en) | 2006-06-22 | 2007-12-21 | Coating device and method for coating medical device with bioactive peptide |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/767,391 Continuation-In-Part US7981862B2 (en) | 2002-08-20 | 2007-06-22 | Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis |
Publications (1)
Publication Number | Publication Date |
---|---|
US20080160169A1 true US20080160169A1 (en) | 2008-07-03 |
Family
ID=38834432
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/767,391 Active 2024-09-15 US7981862B2 (en) | 2002-08-20 | 2007-06-22 | Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US11/963,677 Abandoned US20080160169A1 (en) | 2006-06-22 | 2007-12-21 | Coating device and method for coating medical device with bioactive peptide |
US13/186,165 Ceased US8796212B2 (en) | 2002-08-20 | 2011-07-19 | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US14/452,304 Active US10246499B2 (en) | 2002-08-20 | 2014-08-05 | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US15/230,189 Expired - Lifetime USRE47115E1 (en) | 2003-08-19 | 2016-08-05 | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US15/819,444 Active US10174088B2 (en) | 2006-06-22 | 2017-11-21 | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US16/358,343 Active US11078244B2 (en) | 2006-06-22 | 2019-03-19 | Composition and method for delivery of BMP-2 amplifler/co-activator for enhancement of osteogenesis |
US17/443,012 Pending US20210347838A1 (en) | 2006-06-22 | 2021-07-19 | Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/767,391 Active 2024-09-15 US7981862B2 (en) | 2002-08-20 | 2007-06-22 | Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis |
Family Applications After (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/186,165 Ceased US8796212B2 (en) | 2002-08-20 | 2011-07-19 | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US14/452,304 Active US10246499B2 (en) | 2002-08-20 | 2014-08-05 | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US15/230,189 Expired - Lifetime USRE47115E1 (en) | 2003-08-19 | 2016-08-05 | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US15/819,444 Active US10174088B2 (en) | 2006-06-22 | 2017-11-21 | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US16/358,343 Active US11078244B2 (en) | 2006-06-22 | 2019-03-19 | Composition and method for delivery of BMP-2 amplifler/co-activator for enhancement of osteogenesis |
US17/443,012 Pending US20210347838A1 (en) | 2006-06-22 | 2021-07-19 | Composition and method for delivery of bmp-2 amplifier/co-activator for enhancement of osteogenesis |
Country Status (5)
Country | Link |
---|---|
US (8) | US7981862B2 (en) |
EP (1) | EP2046350A4 (en) |
JP (1) | JP2009541358A (en) |
CA (1) | CA2692240C (en) |
WO (1) | WO2007150053A2 (en) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040087505A1 (en) * | 2002-08-20 | 2004-05-06 | Pena Louis A. | Synthetic heparin-binding factor analogs |
US20080063622A1 (en) * | 2003-08-19 | 2008-03-13 | Biosurface Engineering Technologies, Inc. | Composition and Method for Delivery of BMP-2 Amplifier/Co-Activator for Enhancement of Osteogenesis |
US20080166392A1 (en) * | 2002-08-20 | 2008-07-10 | Zamora Paul O | Positive Modulator of Bone Morphogenic Protein-2 |
US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
US7820172B1 (en) | 2006-06-01 | 2010-10-26 | Biosurface Engineering Technologies, Inc. | Laminin-derived multi-domain peptides |
US8163717B2 (en) | 2002-08-20 | 2012-04-24 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
US8227411B2 (en) | 2002-08-20 | 2012-07-24 | BioSurface Engineering Technologies, Incle | FGF growth factor analogs |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014123978A2 (en) * | 2013-02-05 | 2014-08-14 | University Of Utah Research Foundation | Implantable devices for bone or joint defects |
WO2016002717A1 (en) * | 2014-06-30 | 2016-01-07 | 国立大学法人名古屋大学 | Bone formation promoter |
KR102361814B1 (en) | 2015-04-10 | 2022-02-11 | 삼성전자주식회사 | Electronic apparatus and method for providing information for avoiding ultraviolet |
CN104888287A (en) * | 2015-05-13 | 2015-09-09 | 东华大学 | Method for preparing heparinized lipidosome loaded double-layered intravascular stent |
WO2017003461A1 (en) | 2015-06-30 | 2017-01-05 | University Of South Florida | Osteoconductive and osteoinductive implant for augmentation, stabilization, or defect reconstruction |
WO2017032859A2 (en) * | 2015-08-25 | 2017-03-02 | Histide Ag | Compounds for inducing tissue formation and uses thereof |
AU2017273857B2 (en) | 2016-06-01 | 2021-08-19 | Athira Pharma, Inc. | Compounds |
Citations (85)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3272204A (en) * | 1965-09-22 | 1966-09-13 | Ethicon Inc | Absorbable collagen prosthetic implant with non-absorbable reinforcing strands |
US4172128A (en) * | 1975-03-26 | 1979-10-23 | Erhard Thiele | Process of degrading and regenerating bone and tooth material and products |
US4193138A (en) * | 1976-08-20 | 1980-03-18 | Sumitomo Electric Industries, Ltd. | Composite structure vascular prostheses |
US4563350A (en) * | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
US4747848A (en) * | 1984-11-30 | 1988-05-31 | Vascutek Limited | Vascular grafts |
US4842575A (en) * | 1984-01-30 | 1989-06-27 | Meadox Medicals, Inc. | Method for forming impregnated synthetic vascular grafts |
US5108436A (en) * | 1988-09-29 | 1992-04-28 | Collagen Corporation | Implant fixation |
US5197977A (en) * | 1984-01-30 | 1993-03-30 | Meadox Medicals, Inc. | Drug delivery collagen-impregnated synthetic vascular graft |
US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5509899A (en) * | 1994-09-22 | 1996-04-23 | Boston Scientific Corp. | Medical device with lubricious coating |
US5608035A (en) * | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5635597A (en) * | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
US5643873A (en) * | 1992-05-06 | 1997-07-01 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1 |
US5648458A (en) * | 1992-05-06 | 1997-07-15 | Affymax Technologies N.V. | Peptides and compounds that bind to ELAM-1 |
US5650234A (en) * | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5665114A (en) * | 1994-08-12 | 1997-09-09 | Meadox Medicals, Inc. | Tubular expanded polytetrafluoroethylene implantable prostheses |
US5668110A (en) * | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5728802A (en) * | 1992-05-06 | 1998-03-17 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1) |
US5759515A (en) * | 1989-08-09 | 1998-06-02 | Rhomed Incorporated | Polyvalent peptide pharmaceutical applications |
US5770704A (en) * | 1992-05-18 | 1998-06-23 | Genentech, Inc. | Receptor activation with inactive hepatocyte growth factor ligands |
US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5786331A (en) * | 1994-02-02 | 1998-07-28 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5789182A (en) * | 1990-12-20 | 1998-08-04 | The Children's Medical Center Corporation | System for assaying binding to a heparin-binding growth factor receptor |
US5861476A (en) * | 1994-02-02 | 1999-01-19 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5866113A (en) * | 1996-05-31 | 1999-02-02 | Medtronic, Inc. | Medical device with biomolecule-coated surface graft matrix |
US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US5880096A (en) * | 1994-02-02 | 1999-03-09 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5902799A (en) * | 1989-04-23 | 1999-05-11 | The Trustees Of The University Of Pennsylvania | Methods of modulating tissue growth and regeneration |
US5916585A (en) * | 1996-06-03 | 1999-06-29 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto biodegradable polymers |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US5930995A (en) * | 1996-08-09 | 1999-08-03 | Toyota Jidosha Kabushiki Kaisha | Exhaust gas purification device for a compression-ignition combustion engine |
US5945457A (en) * | 1997-10-01 | 1999-08-31 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science | Process for preparing biologically compatible polymers and their use in medical devices |
US5952474A (en) * | 1992-08-28 | 1999-09-14 | The Public Health Research Institute Of The City Of New York, Inc. | Fusion glycoproteins |
US5955588A (en) * | 1997-12-22 | 1999-09-21 | Innerdyne, Inc. | Non-thrombogenic coating composition and methods for using same |
US6011002A (en) * | 1994-04-08 | 2000-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Circularly permuted ligands and circularly permuted chimeric molecules |
US6030812A (en) * | 1992-11-24 | 2000-02-29 | G. D. Searle & Company | Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors |
US6051648A (en) * | 1995-12-18 | 2000-04-18 | Cohesion Technologies, Inc. | Crosslinked polymer compositions and methods for their use |
US6096798A (en) * | 1996-04-30 | 2000-08-01 | Luthra; Ajay Kumar | Non-thrombogenic and anti-thrombogenic polymers |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6120904A (en) * | 1995-02-01 | 2000-09-19 | Schneider (Usa) Inc. | Medical device coated with interpenetrating network of hydrogel polymers |
US6121236A (en) * | 1998-03-24 | 2000-09-19 | The Children's Medical Center Corporation | Multivalent ligands which modulate angiogenesis |
US6168784B1 (en) * | 1997-09-03 | 2001-01-02 | Gryphon Sciences | N-terminal modifications of RANTES and methods of use |
US6174530B1 (en) * | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
US6174721B1 (en) * | 1994-08-05 | 2001-01-16 | Chiron Corporation | Chimeric proteins |
US6214795B1 (en) * | 1996-11-12 | 2001-04-10 | Praecis Pharmaceuticals, Inc. | Peptide compounds useful for modulating FGF receptor activity |
US6217873B1 (en) * | 1993-05-05 | 2001-04-17 | Gryphon Sciences | Polyoxime compounds and their preparation |
US6231892B1 (en) * | 1990-10-15 | 2001-05-15 | The Board Of Regents, The University Of Texas System | Compositions for coating microcapsules and other surfaces |
US6231600B1 (en) * | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US6248057B1 (en) * | 1998-07-28 | 2001-06-19 | Innerdyne, Inc. | Absorbable brachytherapy and chemotherapy delivery devices and methods |
US6251864B1 (en) * | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6258371B1 (en) * | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
US20010014662A1 (en) * | 1997-03-20 | 2001-08-16 | David C Rueger | Improved osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
US6284503B1 (en) * | 1993-08-20 | 2001-09-04 | University Of Utah Research Foundation | Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces |
US6294359B1 (en) * | 1985-09-12 | 2001-09-25 | Scios Inc. | Human basic fibroblast growth factor analog |
US6342591B1 (en) * | 1998-09-22 | 2002-01-29 | Biosurface Engineering Technologies, Inc. | Amphipathic coating for modulating cellular adhesion composition and methods |
US6350731B1 (en) * | 1993-10-22 | 2002-02-26 | Trigen Limited | Platelet-derived growth factor analogues |
US6368347B1 (en) * | 1999-04-23 | 2002-04-09 | Sulzer Vascutek Ltd. | Expanded polytetrafluoroethylene vascular graft with coating |
US6377349B1 (en) * | 1998-03-30 | 2002-04-23 | Carl Zeiss Jena Gmbh | Arrangement for spectral interferometric optical tomography and surface profile measurement |
US6387978B2 (en) * | 1996-07-11 | 2002-05-14 | Boston Scientific Corporation | Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties |
US6410044B1 (en) * | 1998-03-19 | 2002-06-25 | Surmodics, Inc. | Crosslinkable macromers |
US6426332B1 (en) * | 1997-02-07 | 2002-07-30 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
US6451543B1 (en) * | 1998-08-31 | 2002-09-17 | Gryphon Sciences | Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides |
US6514534B1 (en) * | 1998-08-14 | 2003-02-04 | Incept Llc | Methods for forming regional tissue adherent barriers and drug delivery systems |
US6548634B1 (en) * | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
US6585765B1 (en) * | 2000-06-29 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Implantable device having substances impregnated therein and a method of impregnating the same |
US6596699B2 (en) * | 1998-09-22 | 2003-07-22 | Biosurface Engineering Technologies, Inc. | Nucleic acid coating compositions and methods |
US20040038348A1 (en) * | 2002-08-20 | 2004-02-26 | Pena Louis A. | Synthetic heparin-binding growth factor analogs |
US20040068266A1 (en) * | 2002-10-04 | 2004-04-08 | Yves Delmotte | Devices and methods for mixing and extruding medically useful compositions |
US20040151764A1 (en) * | 2001-07-31 | 2004-08-05 | Biosurface Engineering Technologies, Inc. | Bioactive medical films |
US6846853B2 (en) * | 1999-12-28 | 2005-01-25 | Osteotech, Inc. | Calcium phosphate bone graft material, process for making same and osteoimplant fabricated from same |
US6863899B2 (en) * | 1999-08-13 | 2005-03-08 | Vita Special Purpose Corporation | Composite shaped bodies and methods for their production and use |
US6921811B2 (en) * | 1998-09-22 | 2005-07-26 | Biosurface Engineering Technologies, Inc. | Bioactive coating composition and methods |
US20050196425A1 (en) * | 2002-08-20 | 2005-09-08 | Biosurface Engineering Technologies, Inc. | Positive modulator of bone morphogenic protein-2 |
US6949251B2 (en) * | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
US6984393B2 (en) * | 2001-05-07 | 2006-01-10 | Queen's University At Kingston | Biodegradable elastomer and method of preparing same |
US20060024347A1 (en) * | 2004-02-10 | 2006-02-02 | Biosurface Engineering Technologies, Inc. | Bioactive peptide coatings |
US20060199764A1 (en) * | 2002-08-20 | 2006-09-07 | Biosurface Engineering Technologies, Inc. | FGF growth factor analogs |
US20060205652A1 (en) * | 2004-02-10 | 2006-09-14 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
US7241736B2 (en) * | 2003-11-10 | 2007-07-10 | Angiotech International Ag | Compositions and methods for treating diverticular disease |
US20080063622A1 (en) * | 2003-08-19 | 2008-03-13 | Biosurface Engineering Technologies, Inc. | Composition and Method for Delivery of BMP-2 Amplifier/Co-Activator for Enhancement of Osteogenesis |
US7414028B1 (en) * | 2004-02-04 | 2008-08-19 | Biosurface Engineering Technologies, Inc. | Growth factor analogs |
US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
US20090111743A1 (en) * | 2005-02-25 | 2009-04-30 | Biosurface Engineering Technologies, Inc. | Cysteine-branched heparin-binding growth factor analogs |
US7528105B1 (en) * | 2004-02-10 | 2009-05-05 | Biosurface Engineering Technologies | Heterodimeric chain synthetic heparin-binding growth factor analogs |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6018026A (en) | 1988-01-22 | 2000-01-25 | Zymogenetics, Inc. | Biologically active dimerized and multimerized polypeptide fusions |
FI890312A (en) | 1988-01-25 | 1989-07-26 | Oncogen | AMFIREGULIN: ETT NOWT BIFUNKTIONELLT TILLVAEXT MODULERANDE GLYKOPROTEIN. |
US6919308B2 (en) | 1988-04-08 | 2005-07-19 | Stryker Corporation | Osteogenic devices |
US5202311A (en) | 1988-08-19 | 1993-04-13 | Children's Medical Center Corporation | Stabilized fgf composition |
US5576288A (en) | 1989-04-27 | 1996-11-19 | The Salk Institute For Biological Studies | Fibroblast growth factor conjugates |
GB9101645D0 (en) * | 1991-01-25 | 1991-03-06 | British Bio Technology | Compounds |
US5326695A (en) * | 1992-05-15 | 1994-07-05 | Ludwig Institute For Cancer Research | Platelet derived growth factor agonists |
US5684136A (en) | 1992-05-18 | 1997-11-04 | Genentech, Inc. | Chimeric hepatocyte growth factor (HGF) ligand variants |
US5679673A (en) | 1992-09-24 | 1997-10-21 | The United States Of America, Represented By The Department Of Health And Human Services | Aralkyl bridged diazabicycloalkane derivatives for CNS disorders |
US5674977A (en) | 1993-02-05 | 1997-10-07 | The Ontario Cancer Institute | Branched synthetic peptide conjugate |
US5563046A (en) | 1993-08-02 | 1996-10-08 | Celtrix Pharmaceuticals, Inc. | Fusion polypeptides and proteins |
US5830851A (en) | 1993-11-19 | 1998-11-03 | Affymax Technologies N.V. | Methods of administering peptides that bind to the erythropoietin receptor |
US6638291B1 (en) | 1995-04-20 | 2003-10-28 | Micrus Corporation | Three dimensional, low friction vasoocclusive coil, and method of manufacture |
US6171326B1 (en) | 1998-08-27 | 2001-01-09 | Micrus Corporation | Three dimensional, low friction vasoocclusive coil, and method of manufacture |
US6491965B1 (en) | 1995-11-30 | 2002-12-10 | Hamilton Civic Hospitals Research Development, Inc. | Medical device comprising glycosaminoglycan-antithrombin III/heparin cofactor II conjugates |
US6048964A (en) * | 1995-12-12 | 2000-04-11 | Stryker Corporation | Compositions and therapeutic methods using morphogenic proteins and stimulatory factors |
US6458889B1 (en) | 1995-12-18 | 2002-10-01 | Cohesion Technologies, Inc. | Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use |
US5965532A (en) | 1996-06-28 | 1999-10-12 | Trustees Of Tufts College | Multivalent compounds for crosslinking receptors and uses thereof |
US6306165B1 (en) | 1996-09-13 | 2001-10-23 | Meadox Medicals | ePTFE small caliber vascular grafts with significant patency enhancement via a surface coating which contains covalently bonded heparin |
AU725551B2 (en) | 1996-10-16 | 2000-10-12 | Zymogenetics Inc. | Fibroblast growth factor homologs |
US5994104A (en) | 1996-11-08 | 1999-11-30 | Royal Free Hospital School Of Medicine | Interleukin-12 fusion protein |
DE69828287T2 (en) | 1997-06-13 | 2005-12-15 | Gryphon Therapeutics, Inc., South San Francisco | SOLID PHASE NATIVE CHEMICAL LIGATION OF UNPROTECTED OR N-CYSTEIN PROTECTED PEPTIDES IN AQUEOUS SOLUTIONS |
US6136015A (en) | 1998-08-25 | 2000-10-24 | Micrus Corporation | Vasoocclusive coil |
US6159165A (en) | 1997-12-05 | 2000-12-12 | Micrus Corporation | Three dimensional spherical micro-coils manufactured from radiopaque nickel-titanium microstrand |
US6113629A (en) | 1998-05-01 | 2000-09-05 | Micrus Corporation | Hydrogel for the therapeutic treatment of aneurysms |
US6168615B1 (en) | 1998-05-04 | 2001-01-02 | Micrus Corporation | Method and apparatus for occlusion and reinforcement of aneurysms |
US6656218B1 (en) | 1998-07-24 | 2003-12-02 | Micrus Corporation | Intravascular flow modifier and reinforcement device |
US6165194A (en) | 1998-07-24 | 2000-12-26 | Micrus Corporation | Intravascular flow modifier and reinforcement device |
US6818018B1 (en) | 1998-08-14 | 2004-11-16 | Incept Llc | In situ polymerizable hydrogels |
US6497729B1 (en) | 1998-11-20 | 2002-12-24 | The University Of Connecticut | Implant coating for control of tissue/implant interactions |
US6102932A (en) | 1998-12-15 | 2000-08-15 | Micrus Corporation | Intravascular device push wire delivery system |
US6383204B1 (en) | 1998-12-15 | 2002-05-07 | Micrus Corporation | Variable stiffness coil for vasoocclusive devices |
WO2000045870A1 (en) * | 1999-02-04 | 2000-08-10 | Sdgi Holdings, Inc. | Osteogenic paste compositions and uses thereof |
DE19906096A1 (en) | 1999-02-13 | 2000-08-17 | Walter Sebald | Protein with a heparin-binding epitope |
US6221066B1 (en) | 1999-03-09 | 2001-04-24 | Micrus Corporation | Shape memory segmented detachable coil |
WO2000064481A1 (en) | 1999-04-22 | 2000-11-02 | Eidgenössische Technische Hochschule (ETH) | Controlled release of growth factors from heparin containing matrices |
US6309660B1 (en) | 1999-07-28 | 2001-10-30 | Edwards Lifesciences Corp. | Universal biocompatible coating platform for medical devices |
EP1136524A1 (en) * | 2000-03-22 | 2001-09-26 | SOLVAY POLYOLEFINS EUROPE - BELGIUM (Société Anonyme) | Polyethylene composition and production process for objects formed therefrom |
MXPA03000310A (en) | 2000-07-12 | 2004-12-13 | Gryphon Therapeutics Inc | Polymer-modified bioactive synthetic chemokines, and methods for their manufacture and use. |
EP1318827A4 (en) | 2000-09-08 | 2005-09-14 | Gryphon Therapeutics Inc | Polymer-modified synthetic proteins |
WO2002062823A2 (en) | 2001-02-02 | 2002-08-15 | Yale University | Peptides for facilitating composite receptor expression and translocation of macromolecules |
US6866155B2 (en) | 2002-08-16 | 2005-03-15 | Trion Industries, Inc. | Product display rack |
NZ538646A (en) * | 2002-08-20 | 2008-03-28 | Biosurface Eng Tech Inc | A synthetic heparin-binding growth factor analog |
US7598224B2 (en) | 2002-08-20 | 2009-10-06 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
US7468210B1 (en) | 2002-12-10 | 2008-12-23 | Biosurface Engineering Technologies, Inc. | Cross-linked heparin coatings and methods |
US7351280B2 (en) * | 2004-02-10 | 2008-04-01 | New York University | Macroporous, resorbable and injectible calcium phosphate-based cements (MCPC) for bone repair, augmentation, regeneration, and osteoporosis treatment |
US7820172B1 (en) | 2006-06-01 | 2010-10-26 | Biosurface Engineering Technologies, Inc. | Laminin-derived multi-domain peptides |
US9701631B2 (en) * | 2010-12-03 | 2017-07-11 | The Trustees Of The University Of Pennsylvania | TIP60 inhibitors |
WO2012112567A1 (en) * | 2011-02-15 | 2012-08-23 | Georgetown University | Small molecule inhibitors of agbl2 |
-
2007
- 2007-06-22 US US11/767,391 patent/US7981862B2/en active Active
- 2007-06-22 WO PCT/US2007/071946 patent/WO2007150053A2/en active Application Filing
- 2007-06-22 EP EP07798963A patent/EP2046350A4/en not_active Withdrawn
- 2007-06-22 JP JP2009516753A patent/JP2009541358A/en active Pending
- 2007-06-22 CA CA2692240A patent/CA2692240C/en active Active
- 2007-12-21 US US11/963,677 patent/US20080160169A1/en not_active Abandoned
-
2011
- 2011-07-19 US US13/186,165 patent/US8796212B2/en not_active Ceased
-
2014
- 2014-08-05 US US14/452,304 patent/US10246499B2/en active Active
-
2016
- 2016-08-05 US US15/230,189 patent/USRE47115E1/en not_active Expired - Lifetime
-
2017
- 2017-11-21 US US15/819,444 patent/US10174088B2/en active Active
-
2019
- 2019-03-19 US US16/358,343 patent/US11078244B2/en active Active
-
2021
- 2021-07-19 US US17/443,012 patent/US20210347838A1/en active Pending
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3272204A (en) * | 1965-09-22 | 1966-09-13 | Ethicon Inc | Absorbable collagen prosthetic implant with non-absorbable reinforcing strands |
US4172128A (en) * | 1975-03-26 | 1979-10-23 | Erhard Thiele | Process of degrading and regenerating bone and tooth material and products |
US4193138A (en) * | 1976-08-20 | 1980-03-18 | Sumitomo Electric Industries, Ltd. | Composite structure vascular prostheses |
US4842575A (en) * | 1984-01-30 | 1989-06-27 | Meadox Medicals, Inc. | Method for forming impregnated synthetic vascular grafts |
US5197977A (en) * | 1984-01-30 | 1993-03-30 | Meadox Medicals, Inc. | Drug delivery collagen-impregnated synthetic vascular graft |
US4563350A (en) * | 1984-10-24 | 1986-01-07 | Collagen Corporation | Inductive collagen based bone repair preparations |
US4747848A (en) * | 1984-11-30 | 1988-05-31 | Vascutek Limited | Vascular grafts |
US6294359B1 (en) * | 1985-09-12 | 2001-09-25 | Scios Inc. | Human basic fibroblast growth factor analog |
US5108436A (en) * | 1988-09-29 | 1992-04-28 | Collagen Corporation | Implant fixation |
US5510418A (en) * | 1988-11-21 | 1996-04-23 | Collagen Corporation | Glycosaminoglycan-synthetic polymer conjugates |
US5902799A (en) * | 1989-04-23 | 1999-05-11 | The Trustees Of The University Of Pennsylvania | Methods of modulating tissue growth and regeneration |
US5759515A (en) * | 1989-08-09 | 1998-06-02 | Rhomed Incorporated | Polyvalent peptide pharmaceutical applications |
US6231892B1 (en) * | 1990-10-15 | 2001-05-15 | The Board Of Regents, The University Of Texas System | Compositions for coating microcapsules and other surfaces |
US5789182A (en) * | 1990-12-20 | 1998-08-04 | The Children's Medical Center Corporation | System for assaying binding to a heparin-binding growth factor receptor |
US5648458A (en) * | 1992-05-06 | 1997-07-15 | Affymax Technologies N.V. | Peptides and compounds that bind to ELAM-1 |
US5643873A (en) * | 1992-05-06 | 1997-07-01 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelial leukocyte adhesion molecule 1 |
US5728802A (en) * | 1992-05-06 | 1998-03-17 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 (ELAM-1) |
US5786322A (en) * | 1992-05-06 | 1998-07-28 | Affymax Technologies N.V. | Peptides and compounds that bind selectins including endothelium leukocyte adhesion molecule 1 |
US5770704A (en) * | 1992-05-18 | 1998-06-23 | Genentech, Inc. | Receptor activation with inactive hepatocyte growth factor ligands |
US5952474A (en) * | 1992-08-28 | 1999-09-14 | The Public Health Research Institute Of The City Of New York, Inc. | Fusion glycoproteins |
US6030812A (en) * | 1992-11-24 | 2000-02-29 | G. D. Searle & Company | Fusion proteins comprising multiply mutated interleukin-3 (IL-3) polypeptides and second growth factors |
US6217873B1 (en) * | 1993-05-05 | 2001-04-17 | Gryphon Sciences | Polyoxime compounds and their preparation |
US6174530B1 (en) * | 1993-05-05 | 2001-01-16 | Gryphon Sciences | Homogeneous polyoxime compositions and their preparation by parallel assembly |
US6284503B1 (en) * | 1993-08-20 | 2001-09-04 | University Of Utah Research Foundation | Composition and method for regulating the adhesion of cells and biomolecules to hydrophobic surfaces |
US6350731B1 (en) * | 1993-10-22 | 2002-02-26 | Trigen Limited | Platelet-derived growth factor analogues |
US5773569A (en) * | 1993-11-19 | 1998-06-30 | Affymax Technologies N.V. | Compounds and peptides that bind to the erythropoietin receptor |
US5861476A (en) * | 1994-02-02 | 1999-01-19 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5786331A (en) * | 1994-02-02 | 1998-07-28 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5880096A (en) * | 1994-02-02 | 1999-03-09 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5608035A (en) * | 1994-02-02 | 1997-03-04 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-1 receptor |
US5767234A (en) * | 1994-02-02 | 1998-06-16 | Affymax Technologies, N.V. | Peptides and compounds that bind to the IL-1 receptor |
US6011002A (en) * | 1994-04-08 | 2000-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Circularly permuted ligands and circularly permuted chimeric molecules |
US5635597A (en) * | 1994-05-27 | 1997-06-03 | Affymax Technologies, N.V. | Peptides that bind IL-2 receptors |
US6174721B1 (en) * | 1994-08-05 | 2001-01-16 | Chiron Corporation | Chimeric proteins |
US5665114A (en) * | 1994-08-12 | 1997-09-09 | Meadox Medicals, Inc. | Tubular expanded polytetrafluoroethylene implantable prostheses |
US5650234A (en) * | 1994-09-09 | 1997-07-22 | Surface Engineering Technologies, Division Of Innerdyne, Inc. | Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces |
US5509899A (en) * | 1994-09-22 | 1996-04-23 | Boston Scientific Corp. | Medical device with lubricious coating |
US5932462A (en) * | 1995-01-10 | 1999-08-03 | Shearwater Polymers, Inc. | Multiarmed, monofunctional, polymer for coupling to molecules and surfaces |
US6120904A (en) * | 1995-02-01 | 2000-09-19 | Schneider (Usa) Inc. | Medical device coated with interpenetrating network of hydrogel polymers |
US6231600B1 (en) * | 1995-02-22 | 2001-05-15 | Scimed Life Systems, Inc. | Stents with hybrid coating for medical devices |
US5668110A (en) * | 1995-06-07 | 1997-09-16 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5654276A (en) * | 1995-06-07 | 1997-08-05 | Affymax Technologies N.V. | Peptides and compounds that bind to the IL-5 receptor |
US5869451A (en) * | 1995-06-07 | 1999-02-09 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6251864B1 (en) * | 1995-06-07 | 2001-06-26 | Glaxo Group Limited | Peptides and compounds that bind to a receptor |
US6051648A (en) * | 1995-12-18 | 2000-04-18 | Cohesion Technologies, Inc. | Crosslinked polymer compositions and methods for their use |
US6534591B2 (en) * | 1995-12-18 | 2003-03-18 | Cohesion Technologies, Inc. | Cross-linked polymer compositions and methods for their use |
US6096798A (en) * | 1996-04-30 | 2000-08-01 | Luthra; Ajay Kumar | Non-thrombogenic and anti-thrombogenic polymers |
US6406687B1 (en) * | 1996-04-30 | 2002-06-18 | Ajay Kumar Luthra | Non-thrombogenic and anti-thrombogenic polymers |
US5866113A (en) * | 1996-05-31 | 1999-02-02 | Medtronic, Inc. | Medical device with biomolecule-coated surface graft matrix |
US5916585A (en) * | 1996-06-03 | 1999-06-29 | Gore Enterprise Holdings, Inc. | Materials and method for the immobilization of bioactive species onto biodegradable polymers |
US6099562A (en) * | 1996-06-13 | 2000-08-08 | Schneider (Usa) Inc. | Drug coating with topcoat |
US6387978B2 (en) * | 1996-07-11 | 2002-05-14 | Boston Scientific Corporation | Medical devices comprising ionically and non-ionically crosslinked polymer hydrogels having improved mechanical properties |
US5930995A (en) * | 1996-08-09 | 1999-08-03 | Toyota Jidosha Kabushiki Kaisha | Exhaust gas purification device for a compression-ignition combustion engine |
US6214795B1 (en) * | 1996-11-12 | 2001-04-10 | Praecis Pharmaceuticals, Inc. | Peptide compounds useful for modulating FGF receptor activity |
US6426332B1 (en) * | 1997-02-07 | 2002-07-30 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
US7041641B2 (en) * | 1997-03-20 | 2006-05-09 | Stryker Corporation | Osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
US20010014662A1 (en) * | 1997-03-20 | 2001-08-16 | David C Rueger | Improved osteogenic devices and methods of use thereof for repair of endochondral bone and osteochondral defects |
US6168784B1 (en) * | 1997-09-03 | 2001-01-02 | Gryphon Sciences | N-terminal modifications of RANTES and methods of use |
US5945457A (en) * | 1997-10-01 | 1999-08-31 | A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science | Process for preparing biologically compatible polymers and their use in medical devices |
US5955588A (en) * | 1997-12-22 | 1999-09-21 | Innerdyne, Inc. | Non-thrombogenic coating composition and methods for using same |
US6410044B1 (en) * | 1998-03-19 | 2002-06-25 | Surmodics, Inc. | Crosslinkable macromers |
US6121236A (en) * | 1998-03-24 | 2000-09-19 | The Children's Medical Center Corporation | Multivalent ligands which modulate angiogenesis |
US6235716B1 (en) * | 1998-03-24 | 2001-05-22 | Children's Medical Center Corporation | Multivalent ligands which modulate angiogenesis |
US6377349B1 (en) * | 1998-03-30 | 2002-04-23 | Carl Zeiss Jena Gmbh | Arrangement for spectral interferometric optical tomography and surface profile measurement |
US6258371B1 (en) * | 1998-04-03 | 2001-07-10 | Medtronic Inc | Method for making biocompatible medical article |
US6270788B1 (en) * | 1998-04-03 | 2001-08-07 | Medtronic Inc | Implantable medical device |
US6248057B1 (en) * | 1998-07-28 | 2001-06-19 | Innerdyne, Inc. | Absorbable brachytherapy and chemotherapy delivery devices and methods |
US7025990B2 (en) * | 1998-08-14 | 2006-04-11 | Incept Llc | Methods for forming regional tissue adherent barriers and drug delivery systems |
US6514534B1 (en) * | 1998-08-14 | 2003-02-04 | Incept Llc | Methods for forming regional tissue adherent barriers and drug delivery systems |
US6451543B1 (en) * | 1998-08-31 | 2002-09-17 | Gryphon Sciences | Lipid matrix-assisted chemical ligation and synthesis of membrane polypeptides |
US6342591B1 (en) * | 1998-09-22 | 2002-01-29 | Biosurface Engineering Technologies, Inc. | Amphipathic coating for modulating cellular adhesion composition and methods |
US6596699B2 (en) * | 1998-09-22 | 2003-07-22 | Biosurface Engineering Technologies, Inc. | Nucleic acid coating compositions and methods |
US20020115836A1 (en) * | 1998-09-22 | 2002-08-22 | Ray Tsang | Non-thrombogenic coating composition and methods for using same |
US6921811B2 (en) * | 1998-09-22 | 2005-07-26 | Biosurface Engineering Technologies, Inc. | Bioactive coating composition and methods |
US6548634B1 (en) * | 1998-09-30 | 2003-04-15 | Chiron Corporation | Synthetic peptides having FGF receptor affinity |
US6368347B1 (en) * | 1999-04-23 | 2002-04-09 | Sulzer Vascutek Ltd. | Expanded polytetrafluoroethylene vascular graft with coating |
US6863899B2 (en) * | 1999-08-13 | 2005-03-08 | Vita Special Purpose Corporation | Composite shaped bodies and methods for their production and use |
US6846853B2 (en) * | 1999-12-28 | 2005-01-25 | Osteotech, Inc. | Calcium phosphate bone graft material, process for making same and osteoimplant fabricated from same |
US6585765B1 (en) * | 2000-06-29 | 2003-07-01 | Advanced Cardiovascular Systems, Inc. | Implantable device having substances impregnated therein and a method of impregnating the same |
US6949251B2 (en) * | 2001-03-02 | 2005-09-27 | Stryker Corporation | Porous β-tricalcium phosphate granules for regeneration of bone tissue |
US6984393B2 (en) * | 2001-05-07 | 2006-01-10 | Queen's University At Kingston | Biodegradable elastomer and method of preparing same |
US20040151764A1 (en) * | 2001-07-31 | 2004-08-05 | Biosurface Engineering Technologies, Inc. | Bioactive medical films |
US7482427B2 (en) * | 2002-08-20 | 2009-01-27 | Biosurface Engineering Technologies, Inc. | Positive modulator of bone morphogenic protein-2 |
US20050196425A1 (en) * | 2002-08-20 | 2005-09-08 | Biosurface Engineering Technologies, Inc. | Positive modulator of bone morphogenic protein-2 |
US20080166392A1 (en) * | 2002-08-20 | 2008-07-10 | Zamora Paul O | Positive Modulator of Bone Morphogenic Protein-2 |
US20040038348A1 (en) * | 2002-08-20 | 2004-02-26 | Pena Louis A. | Synthetic heparin-binding growth factor analogs |
US20060199764A1 (en) * | 2002-08-20 | 2006-09-07 | Biosurface Engineering Technologies, Inc. | FGF growth factor analogs |
US20040087505A1 (en) * | 2002-08-20 | 2004-05-06 | Pena Louis A. | Synthetic heparin-binding factor analogs |
US7166574B2 (en) * | 2002-08-20 | 2007-01-23 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding growth factor analogs |
US20040068266A1 (en) * | 2002-10-04 | 2004-04-08 | Yves Delmotte | Devices and methods for mixing and extruding medically useful compositions |
US20080063622A1 (en) * | 2003-08-19 | 2008-03-13 | Biosurface Engineering Technologies, Inc. | Composition and Method for Delivery of BMP-2 Amplifier/Co-Activator for Enhancement of Osteogenesis |
US7241736B2 (en) * | 2003-11-10 | 2007-07-10 | Angiotech International Ag | Compositions and methods for treating diverticular disease |
US7414028B1 (en) * | 2004-02-04 | 2008-08-19 | Biosurface Engineering Technologies, Inc. | Growth factor analogs |
US20090143566A1 (en) * | 2004-02-04 | 2009-06-04 | Biosurface Engineering Technologies, Inc. | Growth Factor Analogs |
US20060205652A1 (en) * | 2004-02-10 | 2006-09-14 | Biosurface Engineering Technologies, Inc. | Formulations and methods for delivery of growth factor analogs |
US20060024347A1 (en) * | 2004-02-10 | 2006-02-02 | Biosurface Engineering Technologies, Inc. | Bioactive peptide coatings |
US7528105B1 (en) * | 2004-02-10 | 2009-05-05 | Biosurface Engineering Technologies | Heterodimeric chain synthetic heparin-binding growth factor analogs |
US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
US20090111743A1 (en) * | 2005-02-25 | 2009-04-30 | Biosurface Engineering Technologies, Inc. | Cysteine-branched heparin-binding growth factor analogs |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8796212B2 (en) | 2002-08-20 | 2014-08-05 | Biosurface Engineering Technologies, Inc. | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US20080166392A1 (en) * | 2002-08-20 | 2008-07-10 | Zamora Paul O | Positive Modulator of Bone Morphogenic Protein-2 |
US10611810B2 (en) | 2002-08-20 | 2020-04-07 | Ferring International Center S.A. | Positive modulator of bone morphogenic protein-2 |
US7700563B2 (en) | 2002-08-20 | 2010-04-20 | Biosurface Engineering Technologies, Inc. | Synthetic heparin-binding factor analogs |
US10246499B2 (en) | 2002-08-20 | 2019-04-02 | Ferring B.V. | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US20040087505A1 (en) * | 2002-08-20 | 2004-05-06 | Pena Louis A. | Synthetic heparin-binding factor analogs |
US8163717B2 (en) | 2002-08-20 | 2012-04-24 | Biosurface Engineering Technologies, Inc. | Dual chain synthetic heparin-binding growth factor analogs |
US8227411B2 (en) | 2002-08-20 | 2012-07-24 | BioSurface Engineering Technologies, Incle | FGF growth factor analogs |
US20080063622A1 (en) * | 2003-08-19 | 2008-03-13 | Biosurface Engineering Technologies, Inc. | Composition and Method for Delivery of BMP-2 Amplifier/Co-Activator for Enhancement of Osteogenesis |
USRE47115E1 (en) | 2003-08-19 | 2018-11-06 | Ferring B.V. | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US7981862B2 (en) | 2003-08-19 | 2011-07-19 | Biosurface Engineering Technologies, Inc. | Composition comprising BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US9670258B2 (en) | 2004-02-20 | 2017-06-06 | Ferring B.V. | Positive modulator of bone morphogenic protein-2 |
US8101570B2 (en) | 2005-02-22 | 2012-01-24 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
US20100298218A1 (en) * | 2005-02-22 | 2010-11-25 | Biosurface Engineering Technologies, Inc. | Single Branch Heparin-Binding Growth Factor Analogs |
US20080227696A1 (en) * | 2005-02-22 | 2008-09-18 | Biosurface Engineering Technologies, Inc. | Single branch heparin-binding growth factor analogs |
US7820172B1 (en) | 2006-06-01 | 2010-10-26 | Biosurface Engineering Technologies, Inc. | Laminin-derived multi-domain peptides |
US10174088B2 (en) | 2006-06-22 | 2019-01-08 | Ferring B.V. | Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis |
US11078244B2 (en) | 2006-06-22 | 2021-08-03 | Ferring B.V. | Composition and method for delivery of BMP-2 amplifler/co-activator for enhancement of osteogenesis |
Also Published As
Publication number | Publication date |
---|---|
US20150030656A1 (en) | 2015-01-29 |
CA2692240C (en) | 2018-03-13 |
US20080063622A1 (en) | 2008-03-13 |
CA2692240A1 (en) | 2007-12-27 |
WO2007150053A3 (en) | 2008-04-10 |
US10174088B2 (en) | 2019-01-08 |
EP2046350A4 (en) | 2011-09-14 |
US10246499B2 (en) | 2019-04-02 |
US20190322712A1 (en) | 2019-10-24 |
EP2046350A2 (en) | 2009-04-15 |
US8796212B2 (en) | 2014-08-05 |
US20180100002A1 (en) | 2018-04-12 |
US20210347838A1 (en) | 2021-11-11 |
US7981862B2 (en) | 2011-07-19 |
US11078244B2 (en) | 2021-08-03 |
US20110305741A1 (en) | 2011-12-15 |
WO2007150053B1 (en) | 2008-05-15 |
WO2007150053A2 (en) | 2007-12-27 |
JP2009541358A (en) | 2009-11-26 |
USRE47115E1 (en) | 2018-11-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080160169A1 (en) | Coating device and method for coating medical device with bioactive peptide | |
US5997519A (en) | Fluid collection device | |
Bai et al. | Biomimetic osteogenic peptide with mussel adhesion and osteoimmunomodulatory functions to ameliorate interfacial osseointegration under chronic inflammation | |
Jin et al. | Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries. | |
US9212978B2 (en) | Cytoblock preparation system and methods of use | |
Kishimoto | Microinjection and cytoplasmic transfer in starfish oocytes | |
Raisz | Hormonal regulation of bone growth and remodelling | |
Cameron et al. | In vitro development of the sea urchin male pronucleus | |
Yokose et al. | An estrogen deficiency caused by ovariectomy increases plasma levels of systemic factors that stimulate proliferation and differentiation of osteoblasts in rats | |
Birnbaum et al. | Changes in IGF-I and-II expression and secretion during the proliferation and differentiation of normal rat osteoblasts | |
US20060121597A1 (en) | Cytoblock preparation system and methods of use | |
EP0804727A1 (en) | In vitro angiogenesis assay | |
Choi et al. | Engineered mussel bioglue as a functional osteoinductive binder for grafting of bone substitute particles to accelerate in vivo bone regeneration | |
US20140037593A1 (en) | Tricalcium Phosphate Binding Peptides And Uses Thereof | |
RU2556806C2 (en) | Peptide, capable of regenerating bone tissue and binding with apatite | |
Otto | Microtubules and the regulation of DNA synthesis in fibroblastic cells: A minireview | |
RU2077880C1 (en) | Preparation for use in substitutive therapy of respiratory tract diseases | |
US6372450B1 (en) | Method of treating cells | |
CN111154873B (en) | Molecular marker for detecting migration and invasion capacity of triple negative breast cancer cells and application thereof | |
Willbold et al. | Electrochemical removal of metallic implants from Technovit 9100 New embedded hard and soft tissues prior to histological sectioning | |
CN112824427B (en) | Short peptide for inhibiting glioma and application thereof | |
Parker et al. | Release of bioactive transforming growth factor β 3 from microtextured polymer surfaces in vitro and in vivo | |
Maeda et al. | Effects of mechanical stimulation on gene expression of articular chondrocytes in polylayer culture | |
JP2000505667A (en) | Calcification resistant biomaterial | |
WO2011060349A1 (en) | Methods of modulating mesenchymal stem cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: BIOSURFACE ENGINEERING TECHNOLOGIES, INC., MARYLAN Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:ZAMORA, PAUL O.;ATKINSON, BRENT LEE;REEL/FRAME:020694/0363 Effective date: 20080115 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |